2005 was a productive year for Memory Pharmaceuticals. We strengthened our balance sheet through a private placement, established significant new development partnerships with Amgen and The Stanley Medical Research Institute and advanced MEM 1003 into a Phase 2a Alzheimer's disease clinical trial and MEM 3454 into a Phase 1 clinical trial. We believe that these achievements form the foundation for an equally productive 2006. |